Management Team

Iain MacLeod, LL.M Ph.D

Co-Founder
CEO and Chief Science Officer

Iain is a co-founder and CEO of Aldatu Biosciences. Also serving as Chief Science Officer, Iain is responsible for leading the advancement of Aldatu’s pathogen and drug resistance diagnostic technology in addition to guiding the company’s global health strategy.

Since founding Aldatu Biosciences in 2014, Iain have led the design, development, and validation of over 30 diagnostic tests using Pan Degenerate Amplification and Adaptation (PANDAA), the company’s core technology platform that he developed PANDAA at the Harvard School of Public Health to enable detection of drug resistant variants of HIV, one of the most challenging targets for molecular diagnostics. Aldatu’s HIV-1 drug resistance [HIVDR] genotyping assays are the first to use real-time PCR for the focussed genotyping of resistance mutations in patients failing treatment and have been purchased and independently validated by the National Health Laboratory Services in South Africa.

Iain undertook his post-doctoral training at the Harvard TH Chan School of Public Health, and the Botswana-Harvard AIDS Institute in Gaborone, Botswana, where he focused on HIV drug resistance. Iain maintained an academic appointment at the Harvard TH Chan School of Public Health until 2021.

Iain holds a Ph.D. in Pathology – specializing in molecular virology – from St John’s College, University of Cambridge (2008), and an LL.M. in International Law and B.Sc. in Virology from the University of Glasgow.

Mike Henry

Chief Business Officer

As CBO, Mike leads deal-making at Aldatu. Mike is a molecular diagnostics expert with over 20 years of senior leadership experience in biotechnology business development at Ancestry, Quest Diagnostics, Thermo Fisher, Athena Diagnostics and other life science companies, and in medical technology transfer at academic medical centers. He sold Athena to Quest for $740M in 2011. Mike is an advisor with biotech startups and a member of Berkeley Angel Network.

Mike holds an MBA and an MA Botany from University of California Berkeley and a BS Botany from University of Michigan.

Betsy Wonderly Trainor

VP Development

Betsy is responsible for commercialization strategy, NGO partnership strategy, and other development efforts. Betsy has over 10 years of experience working in emerging markets, focusing on the validation and implementation of infectious disease diagnostics. Prior to Aldatu, Betsy was the VP of Business Development at Daktari Diagnostics, an HIV diagnostics company. She also led the validation and implementation of Ebola diagnostics in West Africa on behaf of FIND (Foundation for Innovative New Diagnostics) in collaboration with the World Health Organization.

Betsy has a B.S in Human Development from Cornell University and is a graduate of the Product Management Program at Berkeley Haas School of Business.

Larry Carrasco

VP Operations

Larry is responsible Lab Management, Operations, Finances, EH&S, HR functions, and day to day business requirements.

Larry has over 15 years of experience working in operations and laboratory management focusing on developing and deploying best practice laboratory support services. Prior to Aldatu, Larry Held the roles of Program Manager and Regional Services Manager at Thermo Fisher Scientific, within their Unity Lab Services group. He has also worked with EMD Serono in their Laboratory Support Group and Quest Diagnostics in their Cytology Department.

Larry studied Biotechnology at Boston University.

Iain MacLeod, LL.M Ph.D

Co-Founder
CEO and Chief Science Officer

Iain is a co-founder and CEO of Aldatu Biosciences. Also serving as Chief Science Officer, Iain is responsible for leading the advancement of Aldatu’s pathogen and drug resistance diagnostic technology in addition to guiding the company’s global health strategy.

 

Since founding Aldatu Biosciences in 2014, Iain have led the design, development, and validation of over 30 diagnostic tests using Pan Degenerate Amplification and Adaptation (PANDAA), the company’s core technology platform that he developed PANDAA at the Harvard School of Public Health to enable detection of drug resistant variants of HIV, one of the most challenging targets for molecular diagnostics. Aldatu’s HIV-1 drug resistance [HIVDR] genotyping assays are the first to use real-time PCR for the focussed genotyping of resistance mutations in patients failing treatment and have been purchased and independently validated by the National Health Laboratory Services in South Africa.

 

Iain undertook his post-doctoral training at the Harvard TH Chan School of Public Health, and the Botswana-Harvard AIDS Institute in Gaborone, Botswana, where he focused on HIV drug resistance. Iain maintained an academic appointment at the Harvard TH Chan School of Public Health until 2021.

Iain holds a Ph.D. in Pathology – specializing in molecular virology – from St John's College, University of Cambridge (2008), and an LL.M. in International Law and B.Sc. in Virology from the University of Glasgow.

Mike Henry

Chief Business Officer

As CBO, Mike leads deal-making at Aldatu. Mike is a molecular diagnostics expert with over 20 years of senior leadership experience in biotechnology business development at Ancestry, Quest Diagnostics, Thermo Fisher, Athena Diagnostics and other life science companies, and in medical technology transfer at academic medical centers. He sold Athena to Quest for $740M in 2011. Mike is an advisor with biotech startups and a member of Berkeley Angel Network.

Mike holds an MBA and an MA Botany from University of California Berkeley and a BS Botany from University of Michigan.

Betsy Wonderly Trainor

VP Development

Betsy is responsible for commercialization strategy, NGO partnership strategy, and other development efforts. Betsy has over 10 years of experience working in emerging markets, focusing on the validation and implementation of infectious disease diagnostics. Prior to Aldatu, Betsy was the VP of Business Development at Daktari Diagnostics, an HIV diagnostics company. She also led the validation and implementation of Ebola diagnostics in West Africa on behaf of FIND (Foundation for Innovative New Diagnostics) in collaboration with the World Health Organization.

Betsy has a B.S in Human Development from Cornell University and is a graduate of the Product Management Program at Berkeley Haas School of Business.

Larry Carrasco

VP Operations

Larry is responsible Lab Management, Operations, Finances, EH&S, HR functions, and day to day business requirements.

Larry has over 15 years of experience working in operations and laboratory management focusing on developing and deploying best practice laboratory support services. Prior to Aldatu, Larry Held the roles of Program Manager and Regional Services Manager at Thermo Fisher Scientific, within their Unity Lab Services group. He has also worked with EMD Serono in their Laboratory Support Group and Quest Diagnostics in their Cytology Department.

Larry studied Biotechnology at Boston University.

Connect with our team

DESIGN

Amanda Lee

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. 

social

Adam Cheise

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. 

Present

Mike Stuart

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. 

engineer

Floyd Staller

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. 

Co-founder & ceo

Donald Milson

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. 

content manager

Mishel Fox

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit.